<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="280">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157503</url>
  </required_header>
  <id_info>
    <org_study_id>4</org_study_id>
    <nct_id>NCT05157503</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia&quot;</brief_title>
  <official_title>&quot;Epidemiology, Approaches to the Diagnosis and Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Autonomous Non-Profit Organization National Society of Onco-Pulmonologists</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Autonomous Non-Profit Organization National Society of Onco-Pulmonologists</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In connection with the transition to the 8th version of the classification of lung cancer&#xD;
      according to the TNM system, there are currently no precise epidemiological data on stage III&#xD;
      NSCLC, clinical characteristics of patients in this group, approaches to therapy and&#xD;
      treatment results in the Russian Federation. The published statistics only provide&#xD;
      information on the overall incidence of stage III lung, trachea and bronchial cancer, which&#xD;
      is about 40%. This observational study will make it possible to characterize the Russian&#xD;
      population of stage III non-small cell lung cancer patients, approaches to choosing a&#xD;
      treatment option for stage III NSCLC and the outcomes of this treatment in real clinical&#xD;
      practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Examine clinical and morphological groups</measure>
    <time_frame>10/01/2023</time_frame>
    <description>gender ratio (husband, wife)&#xD;
smoking status (smoker, non-smoker, past smoker)&#xD;
proportional distribution: squamous cell, adenocarcinoma, dimorphic cancer, others)&#xD;
how many patients with mediastinal lymph node involvement: (N0, N1, N2, N3)&#xD;
detection frequency: PDL (PDL &lt;1, PDL&gt; 1, PDL &lt;49, PDL&gt; 50), EGFR (EGFR + (19.24 exon) EGFR-), (ALK +, ALK -), (ROS-1 +, ROS-1 -) Get information about regional algorithms&#xD;
Variants of treatment tactics:&#xD;
Percentage:&#xD;
a. Surgery&#xD;
v. Chemotherapy&#xD;
-Diagnostic algorithm:&#xD;
a. Morphological verification frequency b. The frequency of confirmation of metastatic lesions within the thoracic lymph nodes c. F</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore clinical approaches</measure>
    <time_frame>10/01/2023</time_frame>
    <description>Percentage of treatment options depending on:&#xD;
a. histological type&#xD;
squamous&#xD;
adenocarcinoma&#xD;
dimorphic&#xD;
3 A st&#xD;
3B st</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic algorithm:</measure>
    <time_frame>10/01/2023</time_frame>
    <description>v. from a variant of molecular genetic disorders&#xD;
PDL &lt;1&#xD;
PDL&gt; 1&#xD;
PDL &lt;49&#xD;
PDL&gt; 50&#xD;
EGFR +</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of treatment options</measure>
    <time_frame>10/01/2023</time_frame>
    <description>from functional status&#xD;
ECOG 1&#xD;
only surgical treatment&#xD;
surgical + drug treatment&#xD;
surgical + drug treatment + radiation therapy&#xD;
drug treatment&#xD;
drug treatment + radiation therapy&#xD;
radiation therapy&#xD;
ECOG 2&#xD;
only surgical treatment&#xD;
surgical + drug treatment&#xD;
surgical + drug treatment + radiation therapy&#xD;
drug treatment&#xD;
drug treatment + radiation therapy&#xD;
radiation therapy&#xD;
ECOG 3&#xD;
only surgical treatment&#xD;
surgical + drug treatment&#xD;
surgical + drug treatment + radiation therapy&#xD;
drug treatment&#xD;
drug treatment + radiation therapy&#xD;
radiation therapy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>-Evaluate the frequency of decision-making as a standard practice vs with an individual decision</measure>
    <time_frame>10/01/2023</time_frame>
    <description>Percentage of treatment options depending on:&#xD;
a. The nature of the progression&#xD;
oligo progression&#xD;
systemic progression&#xD;
b. Prior treatment options v. after surgical treatment&#xD;
d. Afte</description>
  </other_outcome>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Stage III Non-small Cell Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with morphologically proven stage III non-small cell lung cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - stage III non-small cell lung cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - the rest of the disease stage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Konstantin Laktionov, Professor</last_name>
    <phone>+7-903-170-97-95</phone>
    <email>lkoskos@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valeriy Breder, Leading Researcher</last_name>
    <phone>+7-903-199-07-55</phone>
    <email>vbreder@yandex.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Medical Research Center of Oncology. N. N. Blokhin</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

